ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Therapy, complementary"

  • Abstract Number: 1178 • ACR Convergence 2024

    Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?

    Nancy Baker1, Aliza Spielman1 and Robert Edwards2, 1Tufts University, Medford, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Fibromyalgia (FM) is a common and disabling condition characterized by widespread muscular pain. Meditation has been shown to alleviate affective pain in people with…
  • Abstract Number: 1217 • ACR Convergence 2024

    Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California

    Maggie Hui1, Nicholas Jackson2, Angela Pham1, Keren Chen2, David Elashoff2, ziva Cooper3 and Veena Ranganath4, 1David Geffen School of Medicine at UCLA, Los Angeles, 2UCLA Department of Medicine Statistics Core, Los Angeles, 3UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles, 4UCLA, Los Angeles, CA

    Background/Purpose: Approximately 12-20% of Rheumatology patients use cannabis (Fitzcharles 2020, Wipfler 2022, Rampakakis 2023). Despite the legalization of medical cannabis in California more than 2…
  • Abstract Number: 1415 • ACR Convergence 2024

    Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, Alan Baer2, Thomas Grader-Beck3, Margaret Beach4, Blake M. Warner5, Christopher Lessard1, A. Darise Farris1 and Robert Hal Scofield1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins, Baltimore, MD, 4NIH/NIDCR, Arlington, VA, 5National Institutes of Health, Bethesda, MD

    Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…
  • Abstract Number: 1459 • ACR Convergence 2024

    Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

    Michael Nissen1, Adrian Ciurea2, Raphael Micheroli3, Eric Trunk4 and Delphine Courvoisier5, 1Geneva University Hospital, Geneva, Switzerland, 2University Hospital Zurich, Zürich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4Geneva University Hospital, Geenva, Switzerland, 5University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
  • Abstract Number: 1543 • ACR Convergence 2024

    Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

    Amit Saxena1, Zahi Touma2, Edward Vital3, Eric Morand4, Marta Mosca5, Kristin D'Silva6, Peter Wung6, Ling Cheng6, Melitza Iglesias-Rodriguez6, Shelly Kafka6 and Joan Merrill7, 1NYU Grossman School of Medicine, New York, NY, 2University of Toronto, Toronto, ON, Canada, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 4School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 5University of Pisa, Pisa, Italy, 6AbbVie Inc., North Chicago, IL, 7Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: ABBV-599 is a novel combination of elsubrutinib (ELS; a selective Bruton’s tyrosine kinase inhibitor) and upadacitinib (UPA; a selective Janus kinase inhibitor), which targets…
  • Abstract Number: 1544 • ACR Convergence 2024

    Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus

    wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)

    Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
  • Abstract Number: 1574 • ACR Convergence 2024

    ­­­Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort

    Kevin Chevalier1, Benjamin Thoreau2, Marc Michel3, Bertrand Godeau4, Christian AGARD5, Thomas Papo6, Karim Sacré6, Raphaele Seror7, Xavier Mariette8, Patrice Cacoub9, Ygal Benhamou10, Hervé Levesque10, Cécile Goujard11, Olivier Lambotte11, Bernard Bonnotte12, Maxime SAMSON13, Felix Ackermann14, Jean Schmidt15, Pierre Duhaut16, Jean-Emmanuel Kahn17, Thomas Hanslik17, Nathalie Costedoat-chalumeau18, Benjamin Terrier19, Alexis Régent20, bertrand Dunogue2, Pascal cohen21, Veronique LE GUERN22, Eric Hachulla23, Luc Mouthon2 and Benjamin Chaigne24, 1Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, 2Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 32. Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, 4Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, 5Nantes University Hospital, Nantes, France, 6Université Paris Cité, Paris, France, 7Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 8Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 9Sorbonne Université, Paris, 10Department of Internal Medicine, CHU de Rouen, UniRouen, Rouen, France., Rouen, France, 11Université Paris Saclay, Department of Internal Medicine and clinical immunology, Bicêtre hospital, Assistance Publique-Hôpitaux de Paris, UMR1184 Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin-Bicêtre, France, 12Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, 13Dijon University Hospital, Dijon, France, 14Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, 15Department of Internal Medicine and RECIF, Amiens University Hospital, Université Picardie Jules Verne, Amiens, France., Amiens, France, 16Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, AMIENS, France, 17Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, 18University Paris Cité, Paris, France, 19Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 20National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 21National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 22Cochin hospital, Paris, France, 23Department of Internal Medicine and clinical immunology, North-West National Reference Center for Rare Systemic Autoimmune Diseases iques et Auto-Immunes Rares du Nord-Ouest, Hôpital Claude Huriez, Université de Lille, France, Lille, France, 24Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.…
  • Abstract Number: 1677 • ACR Convergence 2024

    Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial

    Ru Li1, Xing Sun1, Suping Niu2, Xiaolin Sun1, Guimin Zheng3, Meilu Liu3, Jiyang Lv4, Gengmin Zhou4, Gang Yuan5, Yujin Ye5, Shuang Wang5, Pingfei Fang6, Qi Tang6, Jin Kang6, Xiaoyue Li7, Chao Sun7, Song Zhang7, Yongjun Mei7, Jian Wang7, He Su7, Lijing Huang8, Chenhui Li8, Chao Liu8, Fengxiao Zhang3, Qingwen Wang4, Niansheng Yang5, Fen Li6, Linjie Chen7, Yi Fang2 and Zhanguo Li9, 1Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 2Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), 4Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), 5Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 8Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), 9Peking univeristy people's hospital, Beijing, China

    Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
  • Abstract Number: 2028 • ACR Convergence 2024

    Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment

    Marta López I Gómez1, Paula García Escudero2, Berta Magallanes López3, Alicia García Dorta4, Beatriz Frade-Sosa5, Meritxell Sallés Lizarzaburu6, Íñigo Rúa-Figueroa7, Dolly Viviana Fiallo Suárez8, Francisco Javier Toyos Sáenz de Miera9, Rafael Benito Melero-Gonzalez10, Diego Dios Santos11, Jose Alberto Miranda12, Clara Garcia Belando13, Giuliano Boselli14, Alina Lucica Boteanu15, Cristina Corrales Selaya16, cristiana sieiro santos17, Elvira Díez Álvarez18, Judit Font19, Elena Riera Alonso20, Ernesto Trallero Araguás21, Eugenia Enríquez Merayo22, Maria Rodriguez-Laguna23, irene monjo24, Ignacio Vázquez Gómez25, Paloma Vela-Casasempere26, Carolina Merino27, Marta Ibáñez Martínez28, José Ángel Hernández Beriain29, ALBERTO MARIANO RUIZ ROMAN30 and Jaime Calvo-Alén31, 1Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, 2Hospital Universitario Araba, Vitoria, 3Hospital de la Santa Creu i Sant Pau, Barcelona, 4Rheumatologist, La Laguna, Spain, 5Hospital Clinic de Barcelona, Barcelona, Spain, 6Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, 7Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 8H. U. de Gran Canaria. Dr. Negrin, H. U. de Gran Canaria, 9H. U. Virgen Macarena, H. U. Virgen Macarena, 10CHU Ourense, O Carballino, Spain, 11C. H. U. A Coruña, C. H. U. A Coruña, 12C. H. U. Lucus Augusti (Lugo), (Lugo), 13H. C. U. Virgen de la Arrixaca, Murcia, 14hospital miguel servet, zaragoza, Aragon, Spain, 15H.U. Ramón y Cajal, Madrid, Spain, 16Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, 17Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 18Complejo Asistencial Universitario de León, León, Spain, 19Hospital Germans Trias i Pujol, Barcelona, Spain, 20Mutua de Terrasa, Barcelona, 21Hospital Vall D'Hebron, Barcelona, Spain, 22Hospital 12 de Octubre, Madrid, 23Resident in Rheumatology, Madrid, Spain, 24University Hospital La Paz, Madrid, Spain, 25H. U. Dr. Peset, Valencia, 26Hospital General Universitario Alicante, Alicante, Spain, 27Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 28Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 29Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, 30Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, 31Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain

    Background/Purpose: Nearly four years since its characterization, management and therapeutic algorithms for VEXAS syndrome remain unclear. This study aims to describe treatment approaches and assess…
  • Abstract Number: 2092 • ACR Convergence 2024

    Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial

    Chenchen Wang1, Timothy McAlindon2, Meghan Short1, Mei Chung3, Ye Chen1, Albert Tai1 and Honorine Ward1, 1Tufts Medical Center, Boston, MA, 2University of Massachusets, Worchester, MA, 3Tufts Medical Center, Brighton, MA

    Background/Purpose: Previous studies show that Tai Chi achieves clinical improvement for osteoarthritis (OA) through multiple pathways. There is evidence for interaction of the gut microbiota…
  • Abstract Number: 2255 • ACR Convergence 2024

    Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective

    Maryia Nikitsina, María Ahijón Lana and Isidoro González-Álvaro, University Hospital La Princesa, Madrid, Madrid, Spain

    Background/Purpose: Nowadays the honing in on sex-specific treatment options is the most productive way to move forward with the larger effort of implementing precision medicine.…
  • Abstract Number: 0160 • ACR Convergence 2024

    Supplement Use in a Diverse Cohort of Individuals with SLE

    Russell Ellyson1, Jinoos Yazdany2, S. Sam Lim3, Brad Pearce3 and Laura Plantinga4, 1Alameda Health System, Highland Hospital, Oakland, CA, 2UCSF, San Francisco, CA, 3Emory University, Atlanta, GA, 4University of California, San Francisco, San Francisco, CA

    Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or…
  • Abstract Number: 2456 • ACR Convergence 2024

    High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis

    François Maillet1, Carine Schmidt1, Vincent Bondet2, Alexandre Bense1, Darragh Duffy3, Luc Mouthon1, Mathieu Paul Rodero4 and Benjamin Chaigne5, 1AP HP, Paris, France, 2INSERM PAsteur Institute, Paris, France, 3Inserm Pasteur Institue, Paris, France, 4Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, 5Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
  • Abstract Number: 0341 • ACR Convergence 2024

    Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease

    Kaito Aoki1, Keigo Shimura1, Toshiki Ohisa1, Akira Ishii1, Mai Sugiyama2, Yuichiro Ota1, Ayumi Nishikawa3, Noriko Sasaki3, Chiho Yamada1 and Shinji Sato2, 1Tokai University School of Medicine, Isehara, Japan, 2Tokai University, Isehara, Japan, 3Tokai University Hachioji Hospital, Hachioji, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
  • Abstract Number: 2535 • ACR Convergence 2024

    The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation

    Chary Lopez-Pedrera1, Beatriz Vellón-García2, Mª Angeles Aguirre-Zamorano3, Sagrario Corrales4, Ismael Sánchez Pareja4, Laura Muñoz-Barrera4, Tomás Cerdó4, Pedro Segui5, Christian Merlo5, María del carmen ábalos-Aguilera5, Nuria Barbarroja4, Alejandro Escudero-Contreras6, Rafaela Ortega-Castro7, José Manuel Villalba8 and Carlos Perez-Sanchez4, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3) / Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 6Reina Sofia University Hospital, Córdoba, Spain, 7Hospital Reina Sofía, Cordoba, Andalucia, Spain, 8Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3), Cordoba, Spain

    Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology